Edison Pharmaceuticals Inc clinical trials
Acquired by PTC Therapeutics, Oct 25, 2019 · source ↗
The registry lists 7 studies whose lead sponsor is Edison Pharmaceuticals Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 3, 2022.
Before and after it joined PTC Therapeutics
- First submitted before Edison Pharmaceuticals Inc became part of PTC Therapeutics
- 7
- First submitted after Edison Pharmaceuticals Inc became part of PTC Therapeutics
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Phase
- Phase 2
- 5
Registry sponsor names on this page
- Edison Pharmaceuticals Inc7 studies
Something wrong with this grouping? Tell us on the PTC Therapeutics page.
Studies
Recruiting first, then most recently updated. Showing 7 of 7. All PTC Therapeutics studies →
- Safety and Biomarker Study of PTC-589 in Participants With Parkinson's DiseaseCompletedNCT02462603Phase 2
Sponsor listed in the registry: Edison Pharmaceuticals Inc · First submitted before Edison Pharmaceuticals Inc became part of PTC Therapeutics
- Analysis of the Glutathione Cycle in Children With Rett SyndromeWithdrawnNCT02360436
Sponsor listed in the registry: Edison Pharmaceuticals Inc · First submitted before Edison Pharmaceuticals Inc became part of PTC Therapeutics
- An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum DisorderWithdrawnNCT02226458Phase 2
Sponsor listed in the registry: Edison Pharmaceuticals Inc · First submitted before Edison Pharmaceuticals Inc became part of PTC Therapeutics
- Phase 2 Study of EPI-743 in Children With Pearson SyndromeTerminatedNCT02104336Phase 2
Sponsor listed in the registry: Edison Pharmaceuticals Inc · First submitted before Edison Pharmaceuticals Inc became part of PTC Therapeutics
- Protective Effects of EPI-743 on Noise-Induced Hearing LossCompletedNCT02257983Phase 2
Sponsor listed in the registry: Edison Pharmaceuticals Inc · First submitted before Edison Pharmaceuticals Inc became part of PTC Therapeutics
- Phase 2 Study of EPI-743 for Treatment of Rett SyndromeCompletedNCT01822249Phase 2
Sponsor listed in the registry: Edison Pharmaceuticals Inc · First submitted before Edison Pharmaceuticals Inc became part of PTC Therapeutics
- Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]No longer availableNCT02300753
Sponsor listed in the registry: Edison Pharmaceuticals Inc · First submitted before Edison Pharmaceuticals Inc became part of PTC Therapeutics